14 March 2017 - French drug major Sanofi and its specialty care global business unit, Sanofi Genzyme, say they are disappointed about the provisional recommendation by the England and Wales medicines cost-effectiveness regulator for one of their drugs.

The UK’s NICE has issued a provisional recommendation to not recommend Cerdelga (eliglustat tartrate) as a first-line oral treatment for adults with type 1 Gaucher disease in England.

THE NICE published its draft guidance today in an Evaluation Consultation Document, though this is not yet final guidance and may be subject to change.

Read The Pharma Letter article

Read NICE Evaluation Consultation Document for eliglustat tartrate